Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Meerut-250005, India.
Curr Top Med Chem. 2020;20(26):2362-2378. doi: 10.2174/1568026620666200922112300.
The article highlights an up-to-date progress in studies on structural and the remedial aspects of novel coronavirus 2019-nCoV, renamed as SARS-CoV-2, leading to the disease COVID-19, a pandemic. In general, all CoVs including SARS-CoV-2 are spherical positive single-stranded RNA viruses containing spike (S) protein, envelope (E) protein, nucleocapsid (N) protein, and membrane (M) protein, where S protein has a Receptor-binding Domain (RBD) that mediates the binding to host cell receptor, Angiotensin Converting Enzyme 2 (ACE2). The article details the repurposing of some drugs to be tried for COVID-19 and presents the status of vaccine development so far. Besides drugs and vaccines, the role of Convalescent Plasma (CP) therapy to treat COVID-19 is also discussed.
本文重点介绍了新型冠状病毒 2019-nCoV(现更名为 SARS-CoV-2)结构和治疗方面的最新研究进展,该病毒导致了 COVID-19 大流行疾病。一般来说,所有冠状病毒包括 SARS-CoV-2 都是球形的正单链 RNA 病毒,包含刺突(S)蛋白、包膜(E)蛋白、核衣壳(N)蛋白和膜(M)蛋白,其中 S 蛋白具有受体结合结构域(RBD),介导与宿主细胞受体血管紧张素转换酶 2(ACE2)的结合。本文详细介绍了一些用于治疗 COVID-19 的药物的再利用情况,并介绍了迄今为止疫苗开发的现状。除了药物和疫苗外,还讨论了恢复期血浆(CP)疗法治疗 COVID-19 的作用。